Form 8-K - Current report:
SEC Accession No. 0001193125-24-271965
Filing Date
2024-12-06
Accepted
2024-12-06 07:06:28
Documents
15
Period of Report
2024-12-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d888673d8k.htm   iXBRL 8-K 34424
2 EX-99.1 d888673dex991.htm EX-99.1 9943
6 GRAPHIC g888673g1205030634414.jpg GRAPHIC 2937
  Complete submission text file 0001193125-24-271965.txt   174301

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA beam-20241205.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE beam-20241205_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE beam-20241205_pre.xml EX-101.PRE 10802
17 EXTRACTED XBRL INSTANCE DOCUMENT d888673d8k_htm.xml XML 3494
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39208 | Film No.: 241530527
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)